© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
May 14, 2021
As breast cancer becomes an increasingly treatable disease, clinicians should provide personalized follow-up care to address varying burdens of symptoms up to 5 years after diagnosis.
May 13, 2021
The KEYNOTE-522 trial met its dual primary endpoints of pathologic complete response and event-free survival, showing a statistically significant and clinically meaningful improvement in EFS compared to neoadjuvant chemotherapy alone.
May 12, 2021
Loneliness and social isolation have been particularly significant problems for patients with cancer during the COVID-19 pandemic, likely due to isolation and social distancing, according to a study published in Cancer.
Data presented at the 2021 ESMO Breast Cancer Virtual Congress showed 29% of recurrent breast cancer biopsies showed conversion either from, or to, HER2-low expression.
May 10, 2021
These findings also suggest that the efficacy of radiotherapy can be improved with drugs that block the PDGFRb protein.
May 07, 2021
The new study evaluated data from 5000 patients with EBC and 3496 with ABC to determine associations between BMI and survival rates across both stages.
May 05, 2021
The study also found that patients with comorbidities such as heart disease and diabetes were more likely to experience a high symptom burden.
April 27, 2021
Clinicians should consider the impact on subsequent therapies, overall survival,
and median time to definitive deterioration with CDK 4/6 inhibitors.
Cynthia Lynch, MD, breast cancer program clinical advisor with Cancer Treatment Centers of America, said oncology pharmacists are vital team members who can help ensure optimal treatment and safety for patients with breast cancer.
April 26, 2021
Oncology experts recommend patients schedule overdue screenings, as pandemic restrictions ease.